Vertex to acquire Alpine Immune Sciences for $4.9 billion
U.S.-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotech company focused on the discovery and development of innovative protein-based immunotherapies.
The transaction has been unanimously approved by the boards of directors of both companies and is expected to close later this quarter.
Alpine's leading molecule, povetacicept (ALPN-303), is a dual antagonist of BAFF (B-cell activating factor) and APRIL (proliferation-inducing ligand). Povetacicept has shown potential best-in-class efficacy in IgA nephropathy (IgAN) through Phase 2 development, the companies said in a joint statement. IgAN is a severe, progressive autoimmune kidney disease that can lead to end-stage renal disease. To date, there are no approved treatments for the underlying cause of IgAN. Povetacicept is expected to enter Phase 3 clinical development in the second half of 2024.
Due to its mechanism of action as a dual BAFF/APRIL antagonist, povetacicept has the potential to benefit patients with other severe renal autoimmune diseases.
You May Interested In
2026-08-31
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Profits Are Rising, but So Are the Risks—China’s Coatings Industry Is Living Through Its Most Awkward Year
-
German Chemical Industry Output Slumps to Lowest Utilization Rate Since 1991
-
“Clearing the Floor”: DKSH’s Privatization of Its Malaysian Subsidiary Signals a Silent Power Shift in Asia’s Supply Chain
-
This Is Not a Price Increase Wave but a Full-Blown Cost Squeeze Across China’s Coatings Chain
-
LG Chem Enters Semiconductor Stripper Market for the First Time, Cutting Process Time by 50%
-
Merck Wins Approval for the World’s First Oral PCSK9 Drug, with Potential Annual Sales of $5 Billion
-
Retinol in Cosmetics: Regulatory Tightening and Market Changes
-
Private Equity Firm Acquires Lyons Magnus for About $1 Billion as Beverage and Nutrition Ingredients Consolidate
-
When Soybeans Lose Weight, Fertilizers Take the Stage: The Industrial Chain Reaction Behind U.S. Farm Subsidies
-
The Capital Undercurrent in the Desert: China’s Banks, Saudi Gas, and the “Absent” Chinese Funds
Recommend Reading
-
![South Korea Approves Yeosu Restructuring Plan, Permanently Retiring 1.39 Million Tons of Ethylene Capacity]()
South Korea Approves Yeosu Restructuring Plan, Permanently Retiring 1.39 Million Tons of Ethylene Capacity
-
![Vietnam Drives ASEAN Towards a Modern Economy]()
Vietnam Drives ASEAN Towards a Modern Economy
-
![Qatar LNG Hit by Attack: 17% Export Capacity Lost, $20 Billion Wiped Out]()
Qatar LNG Hit by Attack: 17% Export Capacity Lost, $20 Billion Wiped Out
-
![USDA Puts Fresh Money Into Local Food Markets]()
USDA Puts Fresh Money Into Local Food Markets
-
![MDI Price Surge Hits EMEAI: Is This a Market Correction or the Beginning of a Supply Crisis?]()
MDI Price Surge Hits EMEAI: Is This a Market Correction or the Beginning of a Supply Crisis?
-
![Crude oil prices fall, retail prices of refined oil products in China continue to decrease]()
Crude oil prices fall, retail prices of refined oil products in China continue to decrease
-
![Maintenance Concentration Leads to Cost Decline; April PP Market Experiences Volatile Performance]()
Maintenance Concentration Leads to Cost Decline; April PP Market Experiences Volatile Performance
-
![On January 30, the price of pure benzene in China increased]()
On January 30, the price of pure benzene in China increased
-
![Polyester Bottle Flakes in January Show Initial Weakness, Then Strengthen, Climbing to a Peak at Month’s End Before Reversing]()
Polyester Bottle Flakes in January Show Initial Weakness, Then Strengthen, Climbing to a Peak at Month’s End Before Reversing
-
![China's Phenol Market Surges 62% in 9 Days]()
China's Phenol Market Surges 62% in 9 Days
